{"ticker": {"uuid": "90e18461-595a-4a4a-adad-3f8dab57ac0f", "symbol": "IOVA", "name": "Iovance Biotherapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value", "summary": "Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18.2% on Wednesday without new company news, suggesting a repricing of existing information. This jump added approximately $319 million to its market value, nearly matching its March 31 cash position. The rally is likely linked ", "url": "https://ts2.tech/en/iovance-biotherapeutics-nasdaqiova-jumps-18-adding-a-cash-balance-to-its-market-value/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T15:08:00", "published_display": "15 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up", "summary": "Iovance Biotherapeutics (IOVA) stock is showing an 8.14% increase due to optimism surrounding new cancer therapy developments. The company has filed for a mixed securities shelf to allow flexible capital raises and has granted inducement stock options to 27 new non-executive empl", "url": "https://stockstotrade.com/news/iovance-biotherapeutics-inc-iova-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T12:33:00", "published_display": "15 Jul 2026 12:33", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative", "summary": "Iovance Biotherapeutics (IOVA) has recently refreshed its corporate presentation, leading to significant share price momentum. Despite this, a valuation analysis suggests the stock could be 76% undervalued, with a fair value of $18 compared to its current price of $4.37. The pote", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-could-be-76-undervalued-following-its-refreshed-growth-narrative-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:13", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here\u2019s What\u2019s Important to Note", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-iova-updates-corporate-175155561.html", "source_name": "Insider Monkey", "published_at": "2026-07-09T17:51:55+00:00", "published_display": "09 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/12635305-1c75-37d1-b85c-5a1ced323856/heartflow-vs.-iovance.html", "source_name": "Motley Fool", "published_at": "2026-07-04T14:04:59+00:00", "published_display": "04 Jul 2026 14:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M\u2013$370M and cash runway into 2028", "summary": "Iovance Biotherapeutics has updated its corporate outlook, projecting Q2 2026 revenue of $86M\u2013$88M and full-year 2026 revenue of $350M\u2013$370M, with a cash runway extending into 2028. The company highlights the commercial progress of Amtagvi, its FDA-approved T cell therapy for adv", "url": "https://www.stocktitan.net/sec-filings/IOVA/8-k-iovance-biotherapeutics-inc-reports-material-event-5187c3628574.html", "source_name": "Stock Titan", "published_at": "2026-07-03T20:39:11", "published_display": "03 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA - Why I think Iovance is undervalued", "summary": "The author believes Iovance Biotherapeutics (IOVA) is undervalued, with the market focusing on past setbacks rather than future potential. They highlight the approval of Amtagvi, a TIL therapy, and improving commercial performance, expecting strong revenue growth in 2026. The art", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/ismg0jwg-why-i-think-iovance-is-undervalued", "source_name": "Simply Wall Street", "published_at": "2026-07-03T08:39:54", "published_display": "03 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics focuses on cell therapy pipeline as shares trade on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQY2E4LVNLZFljbm9CQkdTV0s5VHM5YV9saXJUTVB1UUlRb3U2WElDc2l1X29VYjVyTHpMdTZvTEl1Y1ZuN1E0VmZRYndkTW9TRGprRW5ZNzB1NmhqVXZ1WjhfdGw5OHdmbDQ4bTVMalpOMUZyQ0ZZb2d6OVowa3BJX3F3cHZQYlRGWHlkZHR3Q0xveW9XaTF2SlRpOWkxejJZWmJaU1h0VFJtbDBXNVpNTHZ1RDEwZnhpbzkzZ1d6ZlpnWHhVZWpZcVZjbw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) for alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth potential, failing ", "url": "https://www.natlawreview.com/press-releases/did-you-lose-money-iovance-biotherapeutics-inc-iova-levi-korsinsky-urges", "source_name": "The National Law Review", "published_at": "2026-07-03T02:40:44", "published_display": "03 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9rRXc5SmQzbGdSVVljZ0hwMXg3TFYycmR2bHhpMlFBLWkxNzZzN2d5ZHltRzNsMHVpcG1ybF9MRHZZVjg1OFdVTlJQZ0d6UFBOV1o4dUhtX3h2bHdpMTQ5NWdqbTQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics updates corporate presentation, reiterates $350M\u2013$370M FY26 guidance", "summary": "Iovance Biotherapeutics has updated its corporate presentation, reaffirming its revenue guidance for FY2026 at $350M\u2013$370M and Q2 2026 guidance at $86M\u2013$88M. The company reported a cash balance of $319M as of March 31, 2026, with a runway extending into 2028. Key highlights inclu", "url": "https://www.tradingview.com/news/tradingview:216384e542aad:0-iovance-biotherapeutics-updates-corporate-presentation-reiterates-350m-370m-fy26-guidance/", "source_name": "TradingView", "published_at": "2026-07-02T20:39:11", "published_display": "02 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA - Iovance Biotherapeutics Inc Options", "summary": "This article provides a detailed financial overview of Iovance Biotherapeutics Inc. (IOVA), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation, profitability, growt", "url": "https://finviz.com/stock?t=IOVA&p=d&ty=oc&r=m3&ov=chain_strike&s=4.5", "source_name": "Finviz", "published_at": "2026-07-02T14:39:54", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript", "summary": "This article provides the transcript from the Iovance Biotherapeutics Inc Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually, with Chairman Ian Dukes presiding and key officers like Colleen Roche (CFO) and Fred Boit (Interim CEO, President, and", "url": "https://www.gurufocus.com/stock/HAM:2LB/transcripts/8910580", "source_name": "GuruFocus", "published_at": "2026-06-29T13:13:11", "published_display": "29 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Iovance Biotherapeutics Inc \u2013 SWB:2LB", "summary": "This article provides financial information for Iovance Biotherapeutics Inc. It displays the enterprise value to revenue forward for the company, accessible through its listing on the Stuttgart Stock Exchange under the ticker 2LB. The content is primarily a data page from Trading", "url": "https://www.tradingview.com/symbols/SWB-2LB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:39:36", "published_display": "27 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Iovance Biotherapeutics Inc \u2013 SWB:2LB", "summary": "The article provides a single financial metric for Iovance Biotherapeutics Inc (SWB:2LB) on the Stuttgart Stock Exchange: its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded at the time of publication. The content primarily focuse", "url": "https://www.tradingview.com/symbols/SWB-2LB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:21", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Iovance Biotherapeutics, Inc. \u2013 NASDAQ:IOVA", "summary": "This article provides financial information for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), specifically focusing on its forward price-to-sales ratio. It briefly mentions real-time market data providers and copyright information related to financial data. The content is present", "url": "https://www.tradingview.com/symbols/NASDAQ-IOVA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:09:48", "published_display": "27 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Iovance Biotherapeutics Inc \u2013 LS:A2DT49", "summary": "This article provides financial data for Iovance Biotherapeutics Inc (LS:A2DT49), specifically focusing on its forward price-to-sales ratio. It appears to be a section from a financial data platform, likely TradingView, showing stock information and navigational links related to ", "url": "https://www.tradingview.com/symbols/LS-A2DT49/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:39:19", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA)", "summary": "This article provides an overview of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) including its current stock price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, an upcoming earnings report, and past earnings an", "url": "https://www.tradingview.com/symbols/NASDAQ-IOVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:37", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Iovance Biotherapeutics Inc \u2013 LS:A2DT49", "summary": "This page provides financial data specifically on the \"Price to earnings forward\" metric for Iovance Biotherapeutics Inc (LS:A2DT49) from TradingView. The article indicates the market is closed for this stock and presents the data under its financial overview section.", "url": "https://www.tradingview.com/symbols/LS-A2DT49/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:53", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma", "summary": "Iovance Biotherapeutics (IOVA) has received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma, marking its third market authorization after the US and Canada. This approval expands the company's geographic reach and potential revenue streams,", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-wins-australia-approval-for-amtagvi-in-melanoma-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-25T12:39:37", "published_display": "25 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance (IOVA) Surges 9.4% on Regulatory Nod", "summary": "Iovance Biotherapeutics Inc. (IOVA) saw its share price surge by 9.4% after securing conditional approval from Australia's Therapeutic Goods Administration (TGA) for Amtagvi, its tumor-derived T-cell immunotherapy, for advanced melanoma. This marks the company's third marketing a", "url": "https://finance.yahoo.com/healthcare/articles/iovance-iova-surges-9-4-021846945.html", "source_name": "Market source", "published_at": "2026-06-24T04:39:26", "published_display": "24 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands", "summary": "Iovance Biotherapeutics Inc. (IOVA) stock climbed by 8.5% following the conditional approval of its cancer therapy, Amtagvi, in Australia for advanced melanoma. This marks its third global marketing authorization and first T-cell therapy for solid tumors in that market. Additiona", "url": "https://stockstotrade.com/news/iovance-biotherapeutics-inc-iova-news-2026_06_23/", "source_name": "StocksToTrade", "published_at": "2026-06-23T16:11:33", "published_display": "23 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNU3Bmck51VEx4a3NPY0plSFpwdkZGRWh4eVozbkxwVUNUWi1VcC1GRzl6cmhBeFNNUk55QVFtNWhDYi1lbWZQYWtiZkpmWGFJajNPYzF0RWxnci1EdmVWV0hlYnVKUWtBWmFiQVE4SWg2alVzMHpyTjlvNU1pRENLejR0czJtRDhmVzZ3UnRrTDV6M1BXQWozWTk3YWJOc0gxVThBcS01OVk5ODAyZDJyLVk1emJyY2pfaTNzY3FHOENLNUJydS1uYW03d3Y?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeUZISTNIOE4xcGtSaWFKdTNtMVFNdEdWazhyX1gxWnREVGRGRDZZQzVObWNvbVV5Qy1teXloejBLV05TRWVuT0taeDh4SWRsa2hyYzd5QndKTXkybmVOZG96dGFndDhNN0VMRWtMMDJ6WXF1TFpJX3BlOXYxbE9PeQ?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Iovance Biotherapeutics Inc (IOVA), noting its current price momentum score of 6.95 and its trading range between a resistance level of $4.53 and a support level of $3.64. It details various technical indicators like MACD, RSI, and mo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iova/technical", "source_name": "TradingKey", "published_at": "2026-06-23T03:10:11", "published_display": "23 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings", "summary": "Iovance Biotherapeutics (IOVA) recently filed new shelf registrations, providing flexibility for future capital raising and employee incentives. Despite some short-term share price softening, the company has seen strong longer-term momentum with significant year-to-date and 1-yea", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-stock-could-be-532-undervalued-after-new-shelf-filings-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-22T23:10:41", "published_display": "22 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 140,860 shares of its common stock to twenty-seven new, non-executive employees on June 18, 2026. These awards were made under Iovance's Amended and Restated 2021 Inducement Plan in accordance ", "url": "https://www.marketscreener.com/news/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7f5cd3df8ef62d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T14:10:11", "published_display": "22 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules.", "summary": "Iovance Biotherapeutics has approved inducement stock options for 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91 and a three-year vesting period. This move complies with Nasdaq Listing Rule 5635(c)(4) and is intended to promote employee retentio", "url": "https://pluang.com/en/news-feed/iovance-biotherapeutics-berita-hak-pilihan-saham-karyawan", "source_name": "Pluang", "published_at": "2026-06-19T21:41:06", "published_display": "19 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees", "summary": "Iovance Biotherapeutics has granted inducement stock options covering 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91, the closing price on June 18, 2026. These options vest over three years and are part of the company's Amended and Restated 2021", "url": "https://www.quiverquant.com/news/Iovance+Biotherapeutics+Grants+Inducement+Stock+Options+to+27+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-06-19T21:20:00", "published_display": "19 Jun 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Iovance Biotherapeutics Inc (IOVA) has an earnings forecast score of 7.64, ranking 280 out of 388 in its industry. Analysts have an average price target of $9.00 for IOVA, with a \"Buy\" rating from 10 analysts. The company's expected revenue for the next quarter is $87.76M, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iova/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:09:34", "published_display": "18 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Files For Mixed Shelf", "summary": "Iovance Biotherapeutics Inc. has filed for a mixed shelf offering, according to a report from Refinitiv. This type of filing allows a company to offer a variety of securities over a period of time without having to register each offering separately. The news was published on Trad", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Q0LS:0-iovance-biotherapeutics-inc-files-for-mixed-shelf/", "source_name": "TradingView", "published_at": "2026-06-18T22:39:20", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Files Mixed Shelf", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-files-mixed-shelf-205616835.html", "source_name": "MT Newswires", "published_at": "2026-06-18T20:56:16+00:00", "published_display": "18 Jun 2026 20:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director", "summary": "Iovance Biotherapeutics (IOVA) director Ryan D. Maynard was granted 90,316 deferred restricted stock units (DRSUs) as compensation under the company's 2018 Equity Incentive Plan. These units, each representing one share of common stock, will vest upon R. Maynard's continued servi", "url": "https://www.stocktitan.net/sec-filings/IOVA/form-4-iovance-biotherapeutics-inc-insider-trading-activity-39b74cab9e55.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:20", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Stock - Background and strategy snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNdmYzNENhZFpMTzRXOWJpXzBJVTJmZU9ZMkptS2NOQWVCaS01eDRMUzBvVTZnLUQzX1pUeGJvYmZsdE1rWXg5Z2d6bFlieFRBUWxvaGhpOGlQSFpTYXVRM0ZLRERWam43cVFhSWF3LTJBWFJuVTlBSHl6WmxXbjc0M2lTSW02b3RQSXB2bktSTkNGX2l5NmVfMTJUNHEtOTFnUV9BM3RpLTVnTWtZdXd3SVpYUURaaWRXb19lLXNn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds (NASDAQ:IOVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdTktV0tCaEIwSlZPVDZkbklTbWVVNEhVdjZ0dHNIZW15VDBJUTl6MUt4amxqZThITlpzUUpadmt3aHlmR19OZE92bjFMaGdnNjVuVndIanl6eGFBSEdPOS0wZTRpbjh5VXl0UXBuSjJDVVM3VzJzLWZ2YktZcGxQOUdiRXJRVk9LUXhFNDJJa0MzQkhic3NNa2RxS2g1TEc4dzJZcGhWelVSaEhLM2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPY3M2R2l6bzVwX2dOOXRCcDM3Z1VCdU1JWDBidC1lX0xCcHJ3QklkYllXQ0UzeXQwLUx4MnBLSnBzNkJ6TmFNR3pwbERWVU90b2xXX210dWZsMFd6cC05S3ZQUDhEdFk2S2o0ZEp4UFNhbnBHbW9KM2QwRVZCWEpWMlc5RUJGM3hueW5BWXhFMy0?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/amtagvi-approval-boosted-iovance-biotherapeutics-153057776.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:30:57+00:00", "published_display": "13 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/iovance-biotherapeutics-iova-advances-next-182254406.html", "source_name": "Insider Monkey", "published_at": "2026-06-10T18:22:54+00:00", "published_display": "10 Jun 2026 18:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMGcwQ0xlRjlvSC0wNnM2LU03Mjg5cV9BdDdid3BxU3JWelJIbVBvMTlfV2g5bGQwTS1SM0VVa21wVjZSeE9lX3VtZHBwUl9qYUNubkRqTmJPQlZqSkdFMzZGNmd0cVc1UDFyNnFVQTRxME5FUTVjUlpzaTZnRzVSR3pFX1ljcVlKcV8waFdXaWJXdlNUYnRjMlNjeDFtY01qbUZsYlFqYXE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Receives FDA Approval for New Can", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSDBkcGVjWW9iV2F4amw4SWZiaW9ZMTktOWhnSy1vaFJVOVJLbXlaR2ZBWlBoN0xiazhQQW41Q0xfWFRrWXc4NHJYNUVadWxtc05LRFNQMEZhckJwbS1yRHFSWTVvMEFuRDVGdDdINVZlV3gzaUFvbURDRXVVSFNLRzV2Ukp3YnZ5bW1pZWlwdllTTU5nSGxkdjd4NHA2TUJPVkdRQTFNLWNNS3dOZ2JxYVZvOVZpV0F6WW81dngyUlE0eW9La3MxWUgwZkRsc2FmTWNSWQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxObW1zaW0teXRsS2dVSmRJbHA2N1gzTGZyazhxemhJbm1veXNYeThzX09McTk0d3pUY0xNZDh1LWNHWmlmYTROYm9BYjVrdTJySVR2NTVYc0c2Z0ZVWVgzNE5MZFhJTVdmbWRGUC1QSm5iR2d2aWVRVm5fRGc3cXdtTTZOXzVRc1BNaV9vNFBXb3o1b3hPa2dtZDJQV0hEbU44bjdvXzBjQ2FaSHRJdFpDdGdtRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics stock (US4622601007): FDA approval, launch progress and what matters now", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPVktIS0FpaTM1U29FQlZCRHJJYk9Vam9wWTBSX3VVWFRJcktBUWlYNnZDMjctZU9uVXNBYkZGZkMtYVBFWHdTU2xMYXY1X2tkS2pzQXBKSDBremJkSmUyNXJONldVLUdhMUlxUDBCUlVwUl90alR0TU8yVnBMUVREWllfVDE5TU94YWJzMFFfM3BKdlZIMkNEZmE3eHFXMWlsamI4TEJNaklqZk1WYUtuYzM1STQxQzQtcXl3VzhR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Iovance (IOVA): The Best Penny Stock to Buy Before It Explodes", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNcDQtYnVobDg1bHpiajJ5OUVqb3BZSHFUX3ZOa2NSXzU2a0pra01Rc2oyVFFsWE5NM1VDOUdxc2ZlcHlBWi1RdUtwSEtra1RsZGdCXzUxTFJiNjJNZmdfTEFrUGVHQkF5ZG9ZSG5nRUVmUHo3WGtVd2szdjhGc3R0Vw?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "State Street (NASDAQ: IOVA) holds 17.45M shares, 4.2% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPdE02d043X0JySktUUU5uSHdJNl9YdmxOMUhkajF3TUVlNHVNd2IyTkxBUVhsaEFPNklfYVg3Mm8wSkEzUTRFZldBcXVSOGhWR1dRa2hxcURCTndLQ3FfNDNRaVVTbEpZc3dtY1lmeUxiZmt0am5Yem5UbHAyWDBVQXFzR3o4WFJ2bFV4WHZzdkpNU2toa0tKc01vOG16Y0tXcHl4aF9oOVlMVmJxaGoxMk1MMktOTjd1aGVBVkVaSFlKanlyY1NqRUFvZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Iovance Biotherapeutics (IOVA) Trailing Loss Improvement Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics (IOVA) Offering Value After Recent Share Price Volatility?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQMjdPVHJ1VWFQd1FqbndjaFRLSHBzYV9rWWloSFhlZm9nRkZka0xiQVhVUzEySWh5d3c3R1hIb21fRnhuX0FDd1kwYllxMXhFUnQ4MGY5ODlRWmwwR2N6XzgwMndWUUI5S3NmXzBkblN1MXc4d1pkbHJYRGx0cE5Ya1dkZXpSMTNwckMyazByVWZ1c2hHdDJ4ejVxX1VIMUhjaERoTWQ2Zm44cmRVVDVQS1Uwdw?oc=5", "source_name": "IndexBox", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Melanoma Drug Successfully Launched, Yet Iovance\u2019s Stock Has Underperformed the Market for Three Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNYXZZaDh5M2lNRzhTSC1MZW5SU05jS3JkR1FSSzFyYnlmU2J5STJTRGFaZjFKS2lUV0NNU2xHMVdWRTdtblFHUy1ZVTBkVUcwbm9kRWpTVFUxeVpCeTJ5MzVxRmYxWFpzWDFCeUUxZ3VscjVVTmxNOWpiQ1NVci1pTTBkUWM2YXU2cnlyclg2d0I4Yk0ydnhpVjVlbUt4T2pIUVc4WmNRTU5zUkhrYUEtM1N1bVpvVHdxSmNleFlwV1phWEdLN05oWWNFWGpBaHNL?oc=5", "source_name": "NAI500", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxObWxJdTFpTmI3YWItMTNfSm9abGttMjNCaUhRdkdBZWlOTmhIT3ByUGFJTlRrZ2ZHOHRfalpLMnB6SExtbUtjaGNrUXd2UW1Lbm52aFhzNjcyRDl4REFmdUtnVXJuc3hWTUVOektHX05TbkhJMUUxUXFhNTd3aFBFVUZBaDBGWHpUX21vcDhObDVWbzJHcVlhRDUtZ1NjS0o2MnZJMnh1WEdwcmNBclE?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNNnBOemVhc1pFSlZra0lFNGVyeFEwQ1p3czdRUHdfeTFzTlgtQncyQWxieXA1dTg4NldVZ0lMU1dNcnJiVG5HcHBVMmhHTldlOWhGSXh4V0EwVmMwRlBuZy1PZ0RYZ2V0eTdSVVhXWHFMTzQ3WVV3aVY3Sm43cTVnWFA2YmIxY0JnNmc?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQMS1Jc0tiTktPa2x1Tjg3R1RiMVA3UkVUSFpFWVZnd2s1VzhDX2NpeDh3MzNMZlMxcVVVSVhoUlVsX0o4RFhYVWlKeFJ3UURGanVxRS1kU0djdExCbV9zeC1Xb1J1SUpZTXEwNlhPdHN0by0zM0xvWE52RVlQeXdicl9QRWxhaUZQU2VidEduOXBNYjBpNkJEUWJGRQ?oc=5", "source_name": "Market source", "published_at": "2025-08-22T07:00:00+00:00", "published_display": "22 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value", "summary": "Iovance Biotherapeutics (NASDAQ:IOVA) shares surged 18.2% on Wednesday without new company news, suggesting a repricing of existing information. This jump added approximately $319 million to its market value, nearly matching its March 31 cash position. The rally is likely linked ", "url": "https://ts2.tech/en/iovance-biotherapeutics-nasdaqiova-jumps-18-adding-a-cash-balance-to-its-market-value/", "source_name": "TechStock\u00b2", "published_at": "2026-07-15T15:08:00", "published_display": "15 Jul 2026 15:08", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA Stock Holds Range As Capital Plans And Hiring Ramp Up", "summary": "Iovance Biotherapeutics (IOVA) stock is showing an 8.14% increase due to optimism surrounding new cancer therapy developments. The company has filed for a mixed securities shelf to allow flexible capital raises and has granted inducement stock options to 27 new non-executive empl", "url": "https://stockstotrade.com/news/iovance-biotherapeutics-inc-iova-news-2026_07_15/", "source_name": "StocksToTrade", "published_at": "2026-07-15T12:33:00", "published_display": "15 Jul 2026 12:33", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Could Be 76% Undervalued Following Its Refreshed Growth Narrative", "summary": "Iovance Biotherapeutics (IOVA) has recently refreshed its corporate presentation, leading to significant share price momentum. Despite this, a valuation analysis suggests the stock could be 76% undervalued, with a fair value of $18 compared to its current price of $4.37. The pote", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-could-be-76-undervalued-following-its-refreshed-growth-narrative-2026-07-10", "source_name": "Sahm", "published_at": "2026-07-11T13:40:13", "published_display": "11 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Updates its Corporate Presentation, Here\u2019s What\u2019s Important to Note", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-iova-updates-corporate-175155561.html", "source_name": "Insider Monkey", "published_at": "2026-07-09T17:51:55+00:00", "published_display": "09 Jul 2026 17:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/12635305-1c75-37d1-b85c-5a1ced323856/heartflow-vs.-iovance.html", "source_name": "Motley Fool", "published_at": "2026-07-04T14:04:59+00:00", "published_display": "04 Jul 2026 14:04", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M\u2013$370M and cash runway into 2028", "summary": "Iovance Biotherapeutics has updated its corporate outlook, projecting Q2 2026 revenue of $86M\u2013$88M and full-year 2026 revenue of $350M\u2013$370M, with a cash runway extending into 2028. The company highlights the commercial progress of Amtagvi, its FDA-approved T cell therapy for adv", "url": "https://www.stocktitan.net/sec-filings/IOVA/8-k-iovance-biotherapeutics-inc-reports-material-event-5187c3628574.html", "source_name": "Stock Titan", "published_at": "2026-07-03T20:39:11", "published_display": "03 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA - Why I think Iovance is undervalued", "summary": "The author believes Iovance Biotherapeutics (IOVA) is undervalued, with the market focusing on past setbacks rather than future potential. They highlight the approval of Amtagvi, a TIL therapy, and improving commercial performance, expecting strong revenue growth in 2026. The art", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/ismg0jwg-why-i-think-iovance-is-undervalued", "source_name": "Simply Wall Street", "published_at": "2026-07-03T08:39:54", "published_display": "03 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics focuses on cell therapy pipeline as shares trade on Nasdaq", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQY2E4LVNLZFljbm9CQkdTV0s5VHM5YV9saXJUTVB1UUlRb3U2WElDc2l1X29VYjVyTHpMdTZvTEl1Y1ZuN1E0VmZRYndkTW9TRGprRW5ZNzB1NmhqVXZ1WjhfdGw5OHdmbDQ4bTVMalpOMUZyQ0ZZb2d6OVowa3BJX3F3cHZQYlRGWHlkZHR3Q0xveW9XaTF2SlRpOWkxejJZWmJaU1h0VFJtbDBXNVpNTHZ1RDEwZnhpbzkzZ1d6ZlpnWHhVZWpZcVZjbw?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-07-03T07:00:00+00:00", "published_display": "03 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi", "summary": "Levi & Korsinsky LLP has filed a class action securities lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) for alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth potential, failing ", "url": "https://www.natlawreview.com/press-releases/did-you-lose-money-iovance-biotherapeutics-inc-iova-levi-korsinsky-urges", "source_name": "The National Law Review", "published_at": "2026-07-03T02:40:44", "published_display": "03 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 26, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZEFVX3lxTE9rRXc5SmQzbGdSVVljZ0hwMXg3TFYycmR2bHhpMlFBLWkxNzZzN2d5ZHltRzNsMHVpcG1ybF9MRHZZVjg1OFdVTlJQZ0d6UFBOV1o4dUhtX3h2bHdpMTQ5NWdqbTQ?oc=5", "source_name": "ChartMill", "published_at": "2026-07-03T00:00:02+00:00", "published_display": "03 Jul 2026 00:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics updates corporate presentation, reiterates $350M\u2013$370M FY26 guidance", "summary": "Iovance Biotherapeutics has updated its corporate presentation, reaffirming its revenue guidance for FY2026 at $350M\u2013$370M and Q2 2026 guidance at $86M\u2013$88M. The company reported a cash balance of $319M as of March 31, 2026, with a runway extending into 2028. Key highlights inclu", "url": "https://www.tradingview.com/news/tradingview:216384e542aad:0-iovance-biotherapeutics-updates-corporate-presentation-reiterates-350m-370m-fy26-guidance/", "source_name": "TradingView", "published_at": "2026-07-02T20:39:11", "published_display": "02 Jul 2026 20:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA - Iovance Biotherapeutics Inc Options", "summary": "This article provides a detailed financial overview of Iovance Biotherapeutics Inc. (IOVA), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation, profitability, growt", "url": "https://finviz.com/stock?t=IOVA&p=d&ty=oc&r=m3&ov=chain_strike&s=4.5", "source_name": "Finviz", "published_at": "2026-07-02T14:39:54", "published_display": "02 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript", "summary": "This article provides the transcript from the Iovance Biotherapeutics Inc Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually, with Chairman Ian Dukes presiding and key officers like Colleen Roche (CFO) and Fred Boit (Interim CEO, President, and", "url": "https://www.gurufocus.com/stock/HAM:2LB/transcripts/8910580", "source_name": "GuruFocus", "published_at": "2026-06-29T13:13:11", "published_display": "29 Jun 2026 13:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Iovance Biotherapeutics Inc \u2013 SWB:2LB", "summary": "This article provides financial information for Iovance Biotherapeutics Inc. It displays the enterprise value to revenue forward for the company, accessible through its listing on the Stuttgart Stock Exchange under the ticker 2LB. The content is primarily a data page from Trading", "url": "https://www.tradingview.com/symbols/SWB-2LB/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:39:36", "published_display": "27 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Iovance Biotherapeutics Inc \u2013 SWB:2LB", "summary": "The article provides a single financial metric for Iovance Biotherapeutics Inc (SWB:2LB) on the Stuttgart Stock Exchange: its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded at the time of publication. The content primarily focuse", "url": "https://www.tradingview.com/symbols/SWB-2LB/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T05:40:21", "published_display": "27 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Iovance Biotherapeutics, Inc. \u2013 NASDAQ:IOVA", "summary": "This article provides financial information for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), specifically focusing on its forward price-to-sales ratio. It briefly mentions real-time market data providers and copyright information related to financial data. The content is present", "url": "https://www.tradingview.com/symbols/NASDAQ-IOVA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:09:48", "published_display": "27 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Iovance Biotherapeutics Inc \u2013 LS:A2DT49", "summary": "This article provides financial data for Iovance Biotherapeutics Inc (LS:A2DT49), specifically focusing on its forward price-to-sales ratio. It appears to be a section from a financial data platform, likely TradingView, showing stock information and navigational links related to ", "url": "https://www.tradingview.com/symbols/LS-A2DT49/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:39:19", "published_display": "26 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA)", "summary": "This article provides an overview of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) including its current stock price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, an upcoming earnings report, and past earnings an", "url": "https://www.tradingview.com/symbols/NASDAQ-IOVA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T12:39:37", "published_display": "26 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Iovance Biotherapeutics Inc \u2013 LS:A2DT49", "summary": "This page provides financial data specifically on the \"Price to earnings forward\" metric for Iovance Biotherapeutics Inc (LS:A2DT49) from TradingView. The article indicates the market is closed for this stock and presents the data under its financial overview section.", "url": "https://www.tradingview.com/symbols/LS-A2DT49/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:53", "published_display": "26 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma", "summary": "Iovance Biotherapeutics (IOVA) has received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma, marking its third market authorization after the US and Canada. This approval expands the company's geographic reach and potential revenue streams,", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-wins-australia-approval-for-amtagvi-in-melanoma-2026-06-24", "source_name": "Sahm", "published_at": "2026-06-25T12:39:37", "published_display": "25 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance (IOVA) Surges 9.4% on Regulatory Nod", "summary": "Iovance Biotherapeutics Inc. (IOVA) saw its share price surge by 9.4% after securing conditional approval from Australia's Therapeutic Goods Administration (TGA) for Amtagvi, its tumor-derived T-cell immunotherapy, for advanced melanoma. This marks the company's third marketing a", "url": "https://finance.yahoo.com/healthcare/articles/iovance-iova-surges-9-4-021846945.html", "source_name": "Market source", "published_at": "2026-06-24T04:39:26", "published_display": "24 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 92, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands", "summary": "Iovance Biotherapeutics Inc. (IOVA) stock climbed by 8.5% following the conditional approval of its cancer therapy, Amtagvi, in Australia for advanced melanoma. This marks its third global marketing authorization and first T-cell therapy for solid tumors in that market. Additiona", "url": "https://stockstotrade.com/news/iovance-biotherapeutics-inc-iova-news-2026_06_23/", "source_name": "StocksToTrade", "published_at": "2026-06-23T16:11:33", "published_display": "23 Jun 2026 16:11", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNU3Bmck51VEx4a3NPY0plSFpwdkZGRWh4eVozbkxwVUNUWi1VcC1GRzl6cmhBeFNNUk55QVFtNWhDYi1lbWZQYWtiZkpmWGFJajNPYzF0RWxnci1EdmVWV0hlYnVKUWtBWmFiQVE4SWg2alVzMHpyTjlvNU1pRENLejR0czJtRDhmVzZ3UnRrTDV6M1BXQWozWTk3YWJOc0gxVThBcS01OVk5ODAyZDJyLVk1emJyY2pfaTNzY3FHOENLNUJydS1uYW03d3Y?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxPeUZISTNIOE4xcGtSaWFKdTNtMVFNdEdWazhyX1gxWnREVGRGRDZZQzVObWNvbVV5Qy1teXloejBLV05TRWVuT0taeDh4SWRsa2hyYzd5QndKTXkybmVOZG96dGFndDhNN0VMRWtMMDJ6WXF1TFpJX3BlOXYxbE9PeQ?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Iovance Biotherapeutics Inc (IOVA), noting its current price momentum score of 6.95 and its trading range between a resistance level of $4.53 and a support level of $3.64. It details various technical indicators like MACD, RSI, and mo", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iova/technical", "source_name": "TradingKey", "published_at": "2026-06-23T03:10:11", "published_display": "23 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings", "summary": "Iovance Biotherapeutics (IOVA) recently filed new shelf registrations, providing flexibility for future capital raising and employee incentives. Despite some short-term share price softening, the company has seen strong longer-term momentum with significant year-to-date and 1-yea", "url": "https://www.sahmcapital.com/news/content/iovance-biotherapeutics-iova-stock-could-be-532-undervalued-after-new-shelf-filings-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-22T23:10:41", "published_display": "22 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)", "summary": "Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 140,860 shares of its common stock to twenty-seven new, non-executive employees on June 18, 2026. These awards were made under Iovance's Amended and Restated 2021 Inducement Plan in accordance ", "url": "https://www.marketscreener.com/news/iovance-biotherapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-ce7f5cd3df8ef62d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T14:10:11", "published_display": "22 Jun 2026 14:10", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules.", "summary": "Iovance Biotherapeutics has approved inducement stock options for 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91 and a three-year vesting period. This move complies with Nasdaq Listing Rule 5635(c)(4) and is intended to promote employee retentio", "url": "https://pluang.com/en/news-feed/iovance-biotherapeutics-berita-hak-pilihan-saham-karyawan", "source_name": "Pluang", "published_at": "2026-06-19T21:41:06", "published_display": "19 Jun 2026 21:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees", "summary": "Iovance Biotherapeutics has granted inducement stock options covering 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91, the closing price on June 18, 2026. These options vest over three years and are part of the company's Amended and Restated 2021", "url": "https://www.quiverquant.com/news/Iovance+Biotherapeutics+Grants+Inducement+Stock+Options+to+27+New+Employees", "source_name": "Quiver Quantitative", "published_at": "2026-06-19T21:20:00", "published_display": "19 Jun 2026 21:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Iovance Biotherapeutics Inc (IOVA) has an earnings forecast score of 7.64, ranking 280 out of 388 in its industry. Analysts have an average price target of $9.00 for IOVA, with a \"Buy\" rating from 10 analysts. The company's expected revenue for the next quarter is $87.76M, and it", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iova/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T23:09:34", "published_display": "18 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Inc Files For Mixed Shelf", "summary": "Iovance Biotherapeutics Inc. has filed for a mixed shelf offering, according to a report from Refinitiv. This type of filing allows a company to offer a variety of securities over a period of time without having to register each offering separately. The news was published on Trad", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Q0LS:0-iovance-biotherapeutics-inc-files-for-mixed-shelf/", "source_name": "TradingView", "published_at": "2026-06-18T22:39:20", "published_display": "18 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Files Mixed Shelf", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/iovance-biotherapeutics-files-mixed-shelf-205616835.html", "source_name": "MT Newswires", "published_at": "2026-06-18T20:56:16+00:00", "published_display": "18 Jun 2026 20:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director", "summary": "Iovance Biotherapeutics (IOVA) director Ryan D. Maynard was granted 90,316 deferred restricted stock units (DRSUs) as compensation under the company's 2018 Equity Incentive Plan. These units, each representing one share of common stock, will vest upon R. Maynard's continued servi", "url": "https://www.stocktitan.net/sec-filings/IOVA/form-4-iovance-biotherapeutics-inc-insider-trading-activity-39b74cab9e55.html", "source_name": "Stock Titan", "published_at": "2026-06-18T21:39:20", "published_display": "18 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics Stock - Background and strategy snapshot", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNdmYzNENhZFpMTzRXOWJpXzBJVTJmZU9ZMkptS2NOQWVCaS01eDRMUzBvVTZnLUQzX1pUeGJvYmZsdE1rWXg5Z2d6bFlieFRBUWxvaGhpOGlQSFpTYXVRM0ZLRERWam43cVFhSWF3LTJBWFJuVTlBSHl6WmxXbjc0M2lTSW02b3RQSXB2bktSTkNGX2l5NmVfMTJUNHEtOTFnUV9BM3RpLTVnTWtZdXd3SVpYUURaaWRXb19lLXNn?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds (NASDAQ:IOVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNdTktV0tCaEIwSlZPVDZkbklTbWVVNEhVdjZ0dHNIZW15VDBJUTl6MUt4amxqZThITlpzUUpadmt3aHlmR19OZE92bjFMaGdnNjVuVndIanl6eGFBSEdPOS0wZTRpbjh5VXl0UXBuSjJDVVM3VzJzLWZ2YktZcGxQOUdiRXJRVk9LUXhFNDJJa0MzQkhic3NNa2RxS2g1TEc4dzJZcGhWelVSaEhLM2c?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPY3M2R2l6bzVwX2dOOXRCcDM3Z1VCdU1JWDBidC1lX0xCcHJ3QklkYllXQ0UzeXQwLUx4MnBLSnBzNkJ6TmFNR3pwbERWVU90b2xXX210dWZsMFd6cC05S3ZQUDhEdFk2S2o0ZEp4UFNhbnBHbW9KM2QwRVZCWEpWMlc5RUJGM3hueW5BWXhFMy0?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amtagvi Approval Boosted Iovance Biotherapeutics, Inc. (IOVA), But Can the Rally Last?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/amtagvi-approval-boosted-iovance-biotherapeutics-153057776.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:30:57+00:00", "published_display": "13 Jun 2026 15:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/iovance-biotherapeutics-iova-advances-next-182254406.html", "source_name": "Insider Monkey", "published_at": "2026-06-10T18:22:54+00:00", "published_display": "10 Jun 2026 18:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMGcwQ0xlRjlvSC0wNnM2LU03Mjg5cV9BdDdid3BxU3JWelJIbVBvMTlfV2g5bGQwTS1SM0VVa21wVjZSeE9lX3VtZHBwUl9qYUNubkRqTmJPQlZqSkdFMzZGNmd0cVc1UDFyNnFVQTRxME5FUTVjUlpzaTZnRzVSR3pFX1ljcVlKcV8waFdXaWJXdlNUYnRjMlNjeDFtY01qbUZsYlFqYXE?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Receives FDA Approval for New Can", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1AFBVV95cUxNSDBkcGVjWW9iV2F4amw4SWZiaW9ZMTktOWhnSy1vaFJVOVJLbXlaR2ZBWlBoN0xiazhQQW41Q0xfWFRrWXc4NHJYNUVadWxtc05LRFNQMEZhckJwbS1yRHFSWTVvMEFuRDVGdDdINVZlV3gzaUFvbURDRXVVSFNLRzV2Ukp3YnZ5bW1pZWlwdllTTU5nSGxkdjd4NHA2TUJPVkdRQTFNLWNNS3dOZ2JxYVZvOVZpV0F6WW81dngyUlE0eW9La3MxWUgwZkRsc2FmTWNSWQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Iovance Biotherapeutics (IOVA) Valuation After Strong Recent Share Price Momentum", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxObW1zaW0teXRsS2dVSmRJbHA2N1gzTGZyazhxemhJbm1veXNYeThzX09McTk0d3pUY0xNZDh1LWNHWmlmYTROYm9BYjVrdTJySVR2NTVYc0c2Z0ZVWVgzNE5MZFhJTVdmbWRGUC1QSm5iR2d2aWVRVm5fRGc3cXdtTTZOXzVRc1BNaV9vNFBXb3o1b3hPa2dtZDJQV0hEbU44bjdvXzBjQ2FaSHRJdFpDdGdtRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics stock (US4622601007): FDA approval, launch progress and what matters now", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPVktIS0FpaTM1U29FQlZCRHJJYk9Vam9wWTBSX3VVWFRJcktBUWlYNnZDMjctZU9uVXNBYkZGZkMtYVBFWHdTU2xMYXY1X2tkS2pzQXBKSDBremJkSmUyNXJONldVLUdhMUlxUDBCUlVwUl90alR0TU8yVnBMUVREWllfVDE5TU94YWJzMFFfM3BKdlZIMkNEZmE3eHFXMWlsamI4TEJNaklqZk1WYUtuYzM1STQxQzQtcXl3VzhR?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance (IOVA): The Best Penny Stock to Buy Before It Explodes", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxNcDQtYnVobDg1bHpiajJ5OUVqb3BZSHFUX3ZOa2NSXzU2a0pra01Rc2oyVFFsWE5NM1VDOUdxc2ZlcHlBWi1RdUtwSEtra1RsZGdCXzUxTFJiNjJNZmdfTEFrUGVHQkF5ZG9ZSG5nRUVmUHo3WGtVd2szdjhGc3R0Vw?oc=5", "source_name": "Market source", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "State Street (NASDAQ: IOVA) holds 17.45M shares, 4.2% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxPdE02d043X0JySktUUU5uSHdJNl9YdmxOMUhkajF3TUVlNHVNd2IyTkxBUVhsaEFPNklfYVg3Mm8wSkEzUTRFZldBcXVSOGhWR1dRa2hxcURCTndLQ3FfNDNRaVVTbEpZc3dtY1lmeUxiZmt0am5Yem5UbHAyWDBVQXFzR3o4WFJ2bFV4WHZzdkpNU2toa0tKc01vOG16Y0tXcHl4aF9oOVlMVmJxaGoxMk1MMktOTjd1aGVBVkVaSFlKanlyY1NqRUFvZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) First-Quarter Results: Here's What Analysts Are Forecasting For This Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Trailing Loss Improvement Tests Bearish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics (IOVA) Offering Value After Recent Share Price Volatility?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics: Analyzing Growth Potential and Risks After Amtagvi Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQMjdPVHJ1VWFQd1FqbndjaFRLSHBzYV9rWWloSFhlZm9nRkZka0xiQVhVUzEySWh5d3c3R1hIb21fRnhuX0FDd1kwYllxMXhFUnQ4MGY5ODlRWmwwR2N6XzgwMndWUUI5S3NmXzBkblN1MXc4d1pkbHJYRGx0cE5Ya1dkZXpSMTNwckMyazByVWZ1c2hHdDJ4ejVxX1VIMUhjaERoTWQ2Zm44cmRVVDVQS1Uwdw?oc=5", "source_name": "IndexBox", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Melanoma Drug Successfully Launched, Yet Iovance\u2019s Stock Has Underperformed the Market for Three Years", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxNYXZZaDh5M2lNRzhTSC1MZW5SU05jS3JkR1FSSzFyYnlmU2J5STJTRGFaZjFKS2lUV0NNU2xHMVdWRTdtblFHUy1ZVTBkVUcwbm9kRWpTVFUxeVpCeTJ5MzVxRmYxWFpzWDFCeUUxZ3VscjVVTmxNOWpiQ1NVci1pTTBkUWM2YXU2cnlyclg2d0I4Yk0ydnhpVjVlbUt4T2pIUVc4WmNRTU5zUkhrYUEtM1N1bVpvVHdxSmNleFlwV1phWEdLN05oWWNFWGpBaHNL?oc=5", "source_name": "NAI500", "published_at": "2026-04-10T07:00:00+00:00", "published_display": "10 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxObWxJdTFpTmI3YWItMTNfSm9abGttMjNCaUhRdkdBZWlOTmhIT3ByUGFJTlRrZ2ZHOHRfalpLMnB6SExtbUtjaGNrUXd2UW1Lbm52aFhzNjcyRDl4REFmdUtnVXJuc3hWTUVOektHX05TbkhJMUUxUXFhNTd3aFBFVUZBaDBGWHpUX21vcDhObDVWbzJHcVlhRDUtZ1NjS0o2MnZJMnh1WEdwcmNBclE?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Iovance Biotherapeutics Inc. (IOVA) One of the Best Immunotherapy Stocks to Buy According to Hedge Funds?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNNnBOemVhc1pFSlZra0lFNGVyeFEwQ1p3czdRUHdfeTFzTlgtQncyQWxieXA1dTg4NldVZ0lMU1dNcnJiVG5HcHBVMmhHTldlOWhGSXh4V0EwVmMwRlBuZy1PZ0RYZ2V0eTdSVVhXWHFMTzQ3WVV3aVY3Sm43cTVnWFA2YmIxY0JnNmc?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQMS1Jc0tiTktPa2x1Tjg3R1RiMVA3UkVUSFpFWVZnd2s1VzhDX2NpeDh3MzNMZlMxcVVVSVhoUlVsX0o4RFhYVWlKeFJ3UURGanVxRS1kU0djdExCbV9zeC1Xb1J1SUpZTXEwNlhPdHN0by0zM0xvWE52RVlQeXdicl9QRWxhaUZQU2VidEduOXBNYjBpNkJEUWJGRQ?oc=5", "source_name": "Market source", "published_at": "2025-08-22T07:00:00+00:00", "published_display": "22 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 62, "sentiment_summary": {"positive": 26, "negative": 3, "neutral": 33, "score": 57, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.6, "count": 32}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 5.3, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.23, "latest_week": "2026-07-10", "one_week_move": -1.9, "four_week_move": 3.7, "twelve_week_move": 9.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.388745, "market_dynamics_buy_signal": false, "relative_strength": 22.571732, "fair_value_gap": -28.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 45.7934, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.9% over one week, +3.7% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "TradingView", "count": 9}, {"label": "simplywall.st", "count": 5}, {"label": "Sahm", "count": 3}, {"label": "Insider Monkey", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "Ad Hoc News", "count": 3}, {"label": "TechStock\u00b2", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 32}, {"label": "Earnings", "count": 17}, {"label": "Regulatory and legal", "count": 9}, {"label": "Analyst action", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.9% over one week, +3.7% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Iovance Biotherapeutics (NASDAQ:IOVA) jumps 18%, adding a cash balance to its market value"}], "updated_at": "2026-07-16T11:51:15.914707+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}